Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overweight Subjects Clear all
Completed No phase listed Observational

Energy Expenditure and Weight Loss Maintenance

NCT03422380
View directory record Official record
Conditions
Obesity, Weight Change, Body, Weight Loss, Physical Activity
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Timeline
2009 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo, Acetaminophen
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT05762471
View directory record Official record
Conditions
Overweight or Obesity, Type2 Diabetes Mellitus
Interventions
GSBR-1290, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 2, 2026, 5:46 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects

NCT03991299
View directory record Official record
Conditions
Obese, Diabetes Mellitus, Type 2
Interventions
Botox 200 UNT Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2Phase 3 Interventional

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

NCT00134199
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598, sibutramine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
15
States / cities
Clearwater, Florida • Kissimmee, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Nov 2, 2026, 5:46 PM EST
Terminated Phase 3 Interventional

A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients

NCT00483171
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598, Non-pharmacological weight loss program (NPP), Low Calorie Diet
Drug · Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

NCT05296733
View directory record Official record
Conditions
Healthy, Liver Diseases, Obesity
Interventions
BI 456906
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Results available

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

NCT03041792
View directory record Official record
Conditions
Obesity
Interventions
Liraglutide, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

NCT03757130
View directory record Official record
Conditions
Obesity
Interventions
AMG 598, Placebo, Liraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

NCT00747929
View directory record Official record
Conditions
Obesity
Interventions
S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
724 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

NCT05504395
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
CSTI-500
Drug
Lead sponsor
ConSynance Therapeutics
Industry
Eligibility
13 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 4 Interventional Results available

Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band

NCT00543140
View directory record Official record
Conditions
Morbid Obesity
Interventions
REALIZE™ Swedish Adjustable Gastric Band
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years to 60 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Maralixibat, Volixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

NCT00785408
View directory record Official record
Conditions
Obesity, Overweight
Interventions
AC2307, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

NCT02835235
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 3 Interventional

Weight Loss and Exercise in Physically Limited Obese Elderly Subjects

NCT00146133
View directory record Official record
Conditions
Obesity, Frailty, Elderly
Interventions
diet, exercise
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Nov 2, 2026, 5:46 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of PEEP on Heart and Lungs in Obese Subjects

NCT02523352
View directory record Official record
Conditions
Obesity, Pulmonary Atelectasis, Obesity Hypoventilation Syndrome, Magnetic Resonance Imaging, Respiratory Mechanics, Electrical Impedance Tomography, Trans-Thoracic Echocardiography
Interventions
Non-Invasive Ventilation, Esophageal catheter positioning
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 2, 2026, 5:46 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

NCT05419726
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide Injectable Product (not provided by the study)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055
View directory record Official record
Conditions
Weight Loss
Interventions
Placebo, VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00404963
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
placebo, GSK376501
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Nov 2, 2026, 5:46 PM EST
Completed Phase 2 Interventional

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

NCT00563563
View directory record Official record
Conditions
Nicotine Dependence, Overweight, Obesity
Interventions
NB32, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Nov 2, 2026, 5:46 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 2, 2026, 5:46 PM EST